Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Reshma Kewalramani. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Reshma Kewalramani har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:VRTX / Vertex Pharmaceuticals Incorporated | CEO & President, Director | 115 968 |
Director | 186 002 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Reshma Kewalramani. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Reshma Kewalramani som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 5 710 | 115 968 | 5,18 | 389,95 | 2 226 614 | 45 221 722 | |
2025-08-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 4 290 | 110 258 | 4,05 | 389,08 | 1 669 153 | 42 899 183 | |
2025-02-28 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −14 079 | 105 915 | −11,73 | 479,61 | −6 752 429 | 50 797 893 | |
2025-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −9 386 | 119 994 | −7,25 | 483,28 | −4 536 066 | 57 990 700 | |
2025-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −6 553 | 129 380 | −4,82 | 463,46 | −3 037 053 | 59 962 455 | |
2025-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 19 015 | 135 933 | 16,26 | ||||
2025-02-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −8 300 | 116 918 | −6,63 | 467,98 | −3 884 234 | 54 715 286 | |
2025-02-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 20 328 | 125 218 | 19,38 | ||||
2025-02-06 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 29 118 | 104 890 | 38,43 | ||||
2024-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −15 198 | 75 772 | −16,71 | 515,00 | −7 826 970 | 39 022 580 |
2024-08-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −15 202 | 90 970 | −14,32 | 505,00 | −7 677 010 | 45 939 850 |
2024-07-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −15 202 | 106 172 | −12,52 | 497,00 | −7 555 394 | 52 767 484 |
2024-06-14 |
|
4 | DNA |
Ginkgo Bioworks Holdings, Inc.
Class A Common Stock |
M - Exercise | 105 263 | 186 002 | 130,37 | ||||
2024-05-29 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 565 | 121 374 | −1,27 | 457,00 | −715 205 | 55 467 918 |
2024-05-29 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 565 | 122 939 | 1,29 | 187,53 | 293 484 | 23 054 751 | |
2024-05-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −15 202 | 121 374 | −11,13 | 447,00 | −6 795 294 | 54 254 178 |
2024-02-27 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −9 386 | 136 507 | −6,43 | 431,79 | −4 052 781 | 58 942 358 | |
2024-02-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −7 019 | 145 893 | −4,59 | 420,58 | −2 952 051 | 61 359 678 | |
2024-02-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −9 359 | 152 912 | −5,77 | 424,01 | −3 968 310 | 64 836 217 | |
2024-02-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −8 255 | 162 271 | −4,84 | 422,74 | −3 489 719 | 68 598 443 | |
2024-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 20 327 | 170 526 | 13,53 | ||||
2024-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 26 972 | 150 199 | 21,89 | ||||
2024-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 14 516 | 123 227 | 13,35 | ||||
2023-12-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −17 135 | 108 711 | −13,62 | 407,00 | −6 973 945 | 44 245 377 |
2023-12-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 14 077 | 125 846 | 12,59 | 187,53 | 2 639 860 | 23 599 900 | |
2023-12-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 058 | 111 769 | 2,81 | 155,57 | 475 733 | 17 387 903 | |
2023-12-15 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 098 | 108 711 | −4,48 | 397,00 | −2 023 906 | 43 158 267 |
2023-11-15 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 097 | 113 809 | −4,29 | 377,00 | −1 921 569 | 42 905 993 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 828 | 118 906 | −6,18 | 355,00 | −2 778 940 | 42 211 630 |
2023-05-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −38 | 126 652 | −0,03 | 340,19 | −12 927 | 43 085 744 |
2023-05-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 668 | 126 690 | −1,30 | 339,43 | −566 169 | 43 002 387 |
2023-05-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 611 | 128 358 | −1,24 | 338,69 | −545 630 | 43 473 571 |
2023-02-28 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −9 386 | 129 969 | −6,74 | 289,12 | −2 713 680 | 37 576 637 | |
2023-02-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −9 359 | 139 355 | −6,29 | 292,85 | −2 740 783 | 40 810 112 | |
2023-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −5 990 | 148 714 | −3,87 | 298,26 | −1 786 577 | 44 355 438 | |
2023-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −3 372 | 154 704 | −2,13 | 294,33 | −992 481 | 45 534 028 | |
2023-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 26 972 | 158 076 | 20,57 | ||||
2023-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 29 118 | 131 104 | 28,55 | ||||
2023-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 12 388 | 101 986 | 13,83 | ||||
2023-01-27 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 89 598 | −10,04 | 315,05 | −3 150 500 | 28 227 850 |
2022-11-10 |
|
4 | DNA |
Ginkgo Bioworks Holdings, Inc.
Class A Common Stock |
M - Exercise | 9 818 | 80 739 | 13,84 | ||||
2022-08-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −11 689 | 99 598 | −10,50 | 305,06 | −3 565 846 | 30 383 366 |
2022-06-28 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −11 689 | 111 153 | −9,52 | 291,30 | −3 405 006 | 32 378 869 |
2022-06-13 |
|
4 | DNA |
Ginkgo Bioworks Holdings, Inc.
Class A Common Stock |
A - Award | 70 921 | 70 921 | |||||
2022-02-28 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −7 246 | 122 842 | −5,57 | 227,86 | −1 651 074 | 27 990 778 | |
2022-02-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −8 584 | 130 088 | −6,19 | 232,51 | −1 995 866 | 30 246 761 | |
2022-02-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −3 031 | 138 672 | −2,14 | 237,74 | −720 590 | 32 967 881 | |
2022-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 29 117 | 141 703 | 25,86 | ||||
2022-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 29 032 | 112 586 | 34,75 | ||||
2022-02-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 9 800 | 83 554 | 13,29 | ||||
2021-11-23 |
|
4 | DNA |
Ginkgo Bioworks Holdings, Inc.
Restricted Stock Units |
A - Award | 9 818 | 9 818 | |||||
2021-09-20 |
|
4 | DNA |
Ginkgo Bioworks Holdings, Inc.
Stock Option |
A - Award | 17 649 | 17 649 | |||||
2021-09-20 |
|
4 | DNA |
Ginkgo Bioworks Holdings, Inc.
Stock Option |
A - Award | 51 782 | 51 782 | |||||
2021-08-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 4 243 | 73 754 | 6,10 | 196,34 | 833 071 | 14 480 860 | |
2021-08-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 5 757 | 69 511 | 9,03 | 195,14 | 1 123 421 | 13 564 377 | |
2021-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −2 898 | 63 643 | −4,36 | 217,57 | −630 518 | 13 846 808 | |
2021-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −2 080 | 66 541 | −3,03 | 211,75 | −440 440 | 14 090 057 | |
2021-02-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −2 962 | 68 621 | −4,14 | 214,16 | −634 342 | 14 695 873 | |
2021-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 29 031 | 71 583 | 68,22 | ||||
2021-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 12 388 | 42 552 | 41,07 | ||||
2021-02-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 3 516 | 30 164 | 13,19 | ||||
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −509 | 3 058 | −14,27 | ||||
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 564 | 15 642 | −9,09 | ||||
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −93 | 26 626 | −0,35 | 273,27 | −25 414 | 7 276 087 |
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −487 | 26 719 | −1,79 | 272,76 | −132 834 | 7 287 874 |
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −471 | 27 206 | −1,70 | 271,42 | −127 839 | 7 384 253 |
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −870 | 27 677 | −3,05 | 270,36 | −235 213 | 7 482 754 |
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −152 | 28 547 | −0,53 | 269,11 | −40 905 | 7 682 283 |
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 509 | 28 699 | 1,81 | 155,57 | 79 185 | 4 464 703 | |
2020-08-10 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 564 | 28 190 | 5,87 | 187,53 | 293 297 | 5 286 471 | |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −9 | 26 626 | −0,03 | 288,37 | −2 595 | 7 678 140 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −19 | 26 635 | −0,07 | 287,63 | −5 465 | 7 661 025 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −27 | 26 654 | −0,10 | 286,07 | −7 724 | 7 624 910 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 | 26 681 | −0,04 | 283,76 | −2 838 | 7 571 001 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 | 26 691 | −0,01 | 282,74 | −1 131 | 7 546 613 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −6 | 26 695 | −0,02 | 281,74 | −1 690 | 7 521 049 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −9 | 26 701 | −0,03 | 280,47 | −2 524 | 7 488 829 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 | 26 710 | −0,03 | 279,70 | −1 958 | 7 470 787 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −6 | 26 717 | −0,02 | 276,40 | −1 658 | 7 384 579 |
2020-05-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 | 26 723 | −0,01 | 274,37 | −549 | 7 331 990 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −510 | 3 567 | −12,51 | ||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 564 | 17 206 | −8,33 | ||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −134 | 26 626 | −0,50 | 275,17 | −36 873 | 7 326 676 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −864 | 26 760 | −3,13 | 274,04 | −236 771 | 7 333 310 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −360 | 27 624 | −1,29 | 272,77 | −98 197 | 7 534 998 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 27 984 | −1,06 | 271,92 | −81 576 | 7 609 409 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −416 | 28 284 | −1,45 | 270,35 | −112 466 | 7 646 579 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 510 | 28 700 | 1,81 | 155,57 | 79 341 | 4 464 859 | |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 564 | 28 190 | 5,87 | 187,53 | 293 297 | 5 286 471 | |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −111 | 26 626 | −0,42 | 239,13 | −26 543 | 6 367 075 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −420 | 26 737 | −1,55 | 238,28 | −100 078 | 6 370 892 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −320 | 27 157 | −1,16 | 236,71 | −75 747 | 6 428 333 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −340 | 27 477 | −1,22 | 235,36 | −80 022 | 6 466 987 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −660 | 27 817 | −2,32 | 234,41 | −154 711 | 6 520 583 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −440 | 28 477 | −1,52 | 232,35 | −102 234 | 6 616 631 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −450 | 28 917 | −1,53 | 230,88 | −103 896 | 6 676 357 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −893 | 29 367 | −2,95 | 229,72 | −205 140 | 6 746 187 |
2020-02-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −2 898 | 30 260 | −8,74 | 239,23 | −693 289 | 7 239 100 | |
2020-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −129 | 33 158 | −0,39 | 245,75 | −31 702 | 8 148 578 |
2020-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −260 | 33 287 | −0,78 | 244,94 | −63 684 | 8 153 318 |
2020-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −134 | 33 547 | −0,40 | 243,76 | −32 664 | 8 177 417 |
2020-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −540 | 33 681 | −1,58 | 242,62 | −131 015 | 8 171 684 |
2020-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −120 | 34 221 | −0,35 | 241,71 | −29 005 | 8 271 558 |
2020-02-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
F - Taxes | −944 | 34 341 | −2,68 | 241,50 | −227 976 | 8 293 352 | |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −510 | 4 077 | −11,12 | ||||
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −1 564 | 18 770 | −7,69 | ||||
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −129 | 35 285 | −0,36 | 242,47 | −31 279 | 8 555 554 |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −271 | 35 414 | −0,76 | 240,75 | −65 243 | 8 525 920 |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −423 | 35 685 | −1,17 | 239,69 | −101 389 | 8 553 338 |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 251 | 36 108 | −3,35 | 238,76 | −298 689 | 8 621 146 |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | −510 | 37 359 | −1,35 | 155,57 | −79 341 | 5 811 940 | |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | −1 564 | 36 849 | −4,07 | 187,53 | −293 297 | 6 910 293 | |
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 12 387 | 35 285 | 54,10 | ||||
2020-02-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 9 800 | 22 898 | 74,82 | ||||
2019-11-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to buy) |
M - Exercise | −4 692 | 20 334 | −18,75 | ||||
2019-11-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 692 | 13 098 | −26,37 | 219,37 | −1 029 284 | 2 873 308 |
2019-11-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 4 692 | 17 790 | 35,82 | 187,53 | 879 891 | 3 336 159 | |
2019-11-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −61 | 13 098 | −0,46 | 205,95 | −12 563 | 2 697 533 |
2019-11-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −509 | 4 587 | −9,99 | ||||
2019-11-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −509 | 13 098 | −3,74 | 199,00 | −101 291 | 2 606 502 |
2019-11-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 509 | 13 607 | 3,89 | 155,57 | 79 185 | 2 116 841 | |
2019-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −3 057 | 5 096 | −37,50 | ||||
2019-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 057 | 13 098 | −18,92 | 199,00 | −608 343 | 2 606 502 |
2019-10-31 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 3 057 | 16 155 | 23,34 | 155,57 | 475 577 | 2 513 233 | |
2019-10-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −638 | 13 098 | −4,64 | 189,00 | −120 582 | 2 475 522 |
2019-05-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −241 | 13 736 | −1,72 | 165,41 | −39 864 | 2 272 072 |
2019-02-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 13 736 | −0,72 | 188,49 | −18 849 | 2 589 099 |
2019-02-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −202 | 13 836 | −1,44 | 187,27 | −37 829 | 2 591 068 |
2019-02-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 186 | 14 038 | −7,79 | 186,75 | −221 486 | 2 621 596 |
2019-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 25 026 | 25 026 | |||||
2019-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 9 799 | 15 224 | 180,63 | ||||
2019-02-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 3 516 | 5 425 | 184,18 | ||||
2018-10-09 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 305 | 1 909 | −54,70 | 186,95 | −430 920 | 356 888 |
2018-04-02 | 3 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
8 428 | ||||||||
2018-04-02 | 3 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
8 428 | ||||||||
2018-04-02 | 3 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
8 428 | ||||||||
2018-04-02 | 3/A | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
4 214 |